Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
30.32
-0.10 (-0.33%)
At close: Nov 18, 2025, 4:00 PM EST
30.36
+0.04 (0.13%)
After-hours: Nov 18, 2025, 7:20 PM EST
Genmab Revenue
Genmab had revenue of $1.02B in the quarter ending September 30, 2025, with 23.34% growth. This brings the company's revenue in the last twelve months to $3.85B, up 29.57% year-over-year. In the year 2024, Genmab had annual revenue of $2.99B with 22.32% growth.
Revenue (ttm)
$3.85B
Revenue Growth
+29.57%
P/S Ratio
4.75
Revenue / Employee
$1,433,881
Employees
2,682
Market Cap
18.28B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.99B | 545.24M | 22.32% |
| Dec 31, 2023 | 2.44B | 358.99M | 17.23% |
| Dec 31, 2022 | 2.08B | 796.62M | 61.88% |
| Dec 31, 2021 | 1.29B | -374.23M | -22.52% |
| Dec 31, 2020 | 1.66B | 855.79M | 106.20% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GMAB News
- 9 hours ago - Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility - GlobeNewsWire
- 10 hours ago - Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewsWire
- 14 hours ago - Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma - Business Wire
- 8 days ago - Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes - GlobeNewsWire
- 8 days ago - Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility - GlobeNewsWire
- 10 days ago - Genmab A/S (GMAB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 15 days ago - Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting - Business Wire